How the rush to release affordable and accessible versions of weight loss drugs could reshape the fight against ‘diabesity’ ...
A surprising new study suggests that a drug first designed for brain and blood diseases might also help people lose weight ...
Zacks Investment Research on MSN
LLY's next-gen obesity drug meets goal in first phase III study for T2D
Eli Lilly LLY announced positive top-line results from a late-stage study evaluating its experimental once-weekly weight-loss drug, retatrutide, in adults with type II diabetes (T2D) This study, ...
The Danish drugmaker is collaborating with Vivtex, cofounded by billionaire Robert Langer, to quickly iterate oral versions of successors to Ozempic and Wegovy. Ozempic has been a household name for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results